HC Wainwright & Co. Maintains Buy on Rein Therapeutics, Lowers Price Target to $8

Benzinga Newsdesk www.benzinga.com Negative 76.8%

Neg 76.8% Neu 0% Pos 0%

HC Wainwright & Co. analyst Brandon Folkes maintains Rein Therapeutics (NASDAQ:RNTX) with a Buy and lowers the price target from $10 to $8.